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Abstract
Background—Alcoholic liver disease has emerged as a leading indication for hepatic
transplantation, although it is a controversial use of resources. We aimed to examine all aspects of
liver transplantation associated with alcohol abuse.
Methods—Retrospective cohort analysis of 123 alcoholic patients with a median of 7 years follow-
up at one center.
Results—In addition to alcohol, 43 (35%) patients had another possible factor contributing to
cirrhosis. Actuarial patient and graft survival rates were, respectively, 84% and 81% (1 year); 72%
and 66% (5 years); and 63% and 59% (7 years). After transplantation, 18 patients (15%) manifested
21 noncutaneous de novo malignancies, which is significantly more than controls (P=0.0001); upper
aerodigestive squamous carcinomas were overrepresented (P=0.03). Thirteen patients had definitely
relapsed and three others were suspected to have relapsed. Relapse was predicted by daily ethanol
consumption (P=0.0314), but not by duration of pretransplant sobriety or explant histology. No
patient had alcoholic hepatitis after transplantation and neither late onset acute nor chronic rejection
was significantly increased. Multiple regression analyses for predictors of graft failure identified
major biliary/vascular complications (P=0.01), chronic bile duct injury on biopsy (P=0.002), and
pericellular fibrosis on biopsy (P=0.05); graft viral hepatitis was marginally significant (P=0.07) on
univariate analysis.
Conclusions—Alcoholic liver disease is an excellent indication for liver transplantation in those
without coexistent conditions. Recurrent alcoholic liver disease alone is not an important cause of
graft pathology or failure. Potential recipients should be heavily screened before transplantation for
coexistent conditions (e.g., hepatitis C, metabolic diseases) and other target-organ damage, especially
aerodigestive malignancy, which are greater causes of morbidity and mortality than is recurrent
alcohol liver disease.
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INTRODUCTION
Hepatic transplantation is an accepted standard of care for end-stage liver disease. One-year
survival rates approach 80% to 85% and late graft loss from chronic rejection is uncommon
(1). Unfortunately, recurrence of the original disease is emerging as a major problem, affecting
most viral hepatitis patients and 15% to 25% of those with autoimmune liver diseases within
5 years (2,3). End-stage alcoholic liver disease may be an excellent indication for
transplantation, because short-term survival rates are comparable with other indications (4–
6), and drinking relapse can potentially be controlled.
Indeed, alcoholic liver disease has emerged as a leading indication for transplantation (7),
although it is a controversial use of resources (8) because the original disease and recurrence
require “deliberate” patient activity. Studies of alcoholic liver transplant recipients have
therefore justifiably focused on alcohol relapse, hoping to provide support for stringent
pretransplant selection criteria that are intended to minimize disease recurrence. This approach,
however, has deflected attention away from the impact of coexistent diseases such as viral
hepatitis and aerodigestive cancers. A holistic approach that addresses these issues is required.
We undertook this retrospective cohort analysis (123 alcoholic patients, median 7 years follow-
up at one center) to examine all aspects of liver transplantation associated with alcohol abuse.
We aimed to better define the impact of past alcohol use, associated diseases, and drinking
relapse on survival and graft disease.
METHODS
Data Collection
Between January 1991 and December 1992, 123/513 (24%) primary liver allograft recipients
at the University of Pittsburgh had a diagnosis of alcoholic liver disease. The diagnosis was
determined from a consensus of surgical, hepatological, and psychiatric evaluations; patients
had a history of sustained excessive alcohol use (normally≥20 g ethanol/day, women; ≥60 g
ethanol/day, men) with a diagnosis of alcohol abuse or dependence after psychiatric evaluation
in conjunction with laboratory data. Before abstinence, most patients drank on a daily basis;
for others, the average weekly alcohol usage was converted into average daily drinks for
comparison. Daily alcohol consumption, by patient report, was converted to grams of ethanol.
For lifetime ethanol exposure, the average daily amount was multiplied by the duration of
drinking. The criteria for transplant eligibility that related to alcohol use were relatively liberal:
6 months pretransplant sobriety, or rehabilitation, with exceptions in select cases.
Pretransplant serology for hepatitis B and C (EIA-2) virus infection was available in 119
patients, the others were missing serology for hepatitis B (n=1), hepatitis C (n=2), and both
hepatitis B and hepatitis C (n=1). Coexistent disease(s) were discovered primarily during
examination of the native hepatectomy specimens and serologic studies for viral hepatitis
infection. A diagnosis of hemachromatosis was based on the presence of at least 3+ iron
deposited primarily in biliary epithelial cells and hepatocytes, a pattern indicative of
hemachromatosis. Cases with significant iron overload in nonparenchymal cells and periseptal
hepatocytes were not included. A diagnosis of alpha-1-anti-trypsin deficiency was based on
the presence of large (>4 microns) periodic acid-Schiff positive globules, after diastase
digestion, which has been previously shown to correlate with α1-antitrypsin abnormalities
(9).
The histology slides from all native livers and allograft biopsies were reviewed, without
knowledge of the clinical findings, and then correlated with clinical and radiological data to
generate a record of patient follow-up. The necro-inflammatory activity and fibrosis staging
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were carried out according to the modified hepatitis activity index of Ishak et al. (10) Allograft
biopsies were performed for investigation of graft dysfunction. Three patients had no allograft
biopsy. Fifty-two patients had allograft biopsies more than 6 months after transplant (including
failed allografts).
Alcohol relapse was defined as any alcohol use revealed by the patient after transplant, or ad
hoc blood alcohol assays. All patients with abnormal monthly liver biochemistry were
questioned about relapse, but there were no protocol prospective interviews or alcohol assays.
Latest follow-up was taken to be date of death, graft failure, or the latest laboratory test. Where
patients were retransplanted, data pertinent to the first graft was used for statistical analysis.
A comparison group was generated from the other 390 patients receiving primary liver
transplants during the same period. These studies were approved by the local institutional
review board approval (protocol #2105PUHnew).
Statistical Analyses
Statistical analyses included basic descriptive statistics, chi-square and non-parametric tests,
and modeling techniques including logistic and Cox proportional hazards regression. All
models comparing those who underwent transplantation for alcoholic liver disease with the
nonalcoholic group were fit adjusted for age, sex, and severity of illness (UNOS status) at the
time of transplantation. Survival rates were obtained using the Kaplan Meier method. Time-
dependent covariates were used when appropriate. Analyses were performed using Statistical
Analysis System for Windows (version 6.12).
RESULTS
Pretransplantation Characteristics
The study cohort contained 91 men and 32 women, of median age 53 years (range 28–75). All
but one patient had cirrhosis. Alcohol was the only identified factor in 80 (65%), whereas 43
(35%) had another possible contributing factor; these included hepatitis C (20/120 tested, 17%),
hepatitis B and acute acetaminophen toxicity without cirrhosis (1/121, 0.8%),
hemochromatosis (9[including one with α1-anti-trypsin deficiency]/123, 8%), α1-anti-trypsin
deficiency alone (4/123, 3%), sarcoidosis (1/123, 0.8%), epithelioid granulomas of unknown
cause (2/123, 1.6%), and explant hepatitis in seronegative patients (see below, 6/123 5%).
Twelve patients (10%) had hepatocellular carcinoma (T2–T4), and one had an unsuspected
peripheral cholangiocarcinoma.
Complete pretransplant alcohol histories, including nature, quantity, frequency, and duration
of alcohol intake, were available for 110 patients (29 women, 81 men); the remainder had less
complete but adequate documentation of excessive intake. Women reported alcohol
consumption before transplant of median 93 g/day (range 23–675 g/day), and men reported a
median 140 g/day (range 23–955 g/day). The median estimated lifetime intake of alcohol was
408 kg (range 85–3572 kg) for women, and 638 kg (range 51–8038 kg) for men. Men had a
longer median duration of drinking than women (15 years vs. 12 years), whereas women had
a longer median duration of pretransplant sobriety (26 months vs. 12 months).
Native Liver Pathology Review
Fifty-six of 123 native livers (45%) had features suggestive of alcoholic liver disease, including
livers from 9 hepatitis C–infected patients (Table 1). These features included micronodular
cirrhosis, perivenular pericellular fibrosis, central-nodular Mallory's bodies (41 cases), and
steatohepatitis (4 cases; always focal) (11). Twenty-three (34%) of the other 67 livers without
evidence of alcohol injury showed some other insult on histology (Table 1). Six native livers
without alcohol injury showed chronic hepatitis, but were from patients with negative
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pretransplant viral serology. Nevertheless, four of the six patients went on to develop allograft
viral hepatitis B or C after transplantation, suggesting that the pretransplant serology was false
negative. If that assumption is made, then the explant histology did not indicate a cause of the
cirrhosis in 44/123 (36%) patients.
Mallory's bodies (P=0.0044) and steatosis (P=0.0201) were more frequent in patients with
shorter pretransplant sobriety (Table 2). Steatohepatitis (4 cases) was too infrequent for
correlation.
Graft and Patient Survival after Transplantation
Follow-up was available for all patients (median 2543 days). Tables 3 and 4 detail causes of
graft failure and death. Actuarial patient and graft survival rates were, respectively, 84% and
81% (1 year), 83% and 80% (2 years), 72% and 66% (5 years), and 63% and 59% (7 years).
Graft and patient survival did not differ significantly from controls transplanted during the
same period (data not shown). Seventy-one (57%) patients had functioning first allografts at
latest follow-up (median 2647 days, range 1513–2931). Hepatocellular carcinoma recurred in
3 of 12 patients (170, 260, 720 days) and caused death.
Extrahepatic Malignancy after Transplantation
Excluding posttransplant lymphoproliferative disorders (PTLD), 27 patients developed 33 new
malignancies after transplantation. This is significantly more than in nonalcoholic controls
(Table 5; P=0.0001). Eighteen patients (15%) manifested 21 noncutaneous malignancies,
which is also significantly more than controls (P=0.0001); in 7 patients the malignancy was
fatal. The most common primary sites were upper aerodigestive, urogenital, lung, and colonic
(Table 5). Upper aerodigestive squamous carcinomas were overrepresented compared with
controls (P=0.03). Twelve patients (10%) (including three with noncutaneous malignancies)
developed cutaneous malignancy—none fatal. Three patients (2.5%) (including one with
colonic adenocarcinoma) developed PTLD; it was fatal in two.
Alcohol Relapse: Incidence and Impact
Thirteen patients had definite relapse, confirmed in eight by positive blood alcohol tests (on
multiple occasions in four, and >100 mg/dl in six), and admitted by five others. Three patients
relapsed within 6 months after transplantation. Three additional patients had histology
suspicious for relapse, but without other evidence, and denied alcohol use. Logistic regression
using variables of the alcohol history (length of sobriety, duration of drinking, lifetime ethanol
consumption, average drinks per day), native liver histology, and posttransplant liver injury
tests was used to identify markers of relapse after transplantation. Daily ethanol consumption
was significant when all 16 patients were considered (P=0.03), and marginally significant when
only the 13 relapse-confirmed patients were considered (P=0.09). At relapse, the serum
GGTP:ALP ratio was elevated compared with nonrelapsers, whether the 13 known or the 16
known/suspected group was analyzed (relapsers vs. nonrelapsers: 1.13 vs. 0.63, median;
P=0.017). Other factors analyzed, including steatosis and Mallory bodies in the native liver,
duration of pretransplant sobriety, and estimated lifetime ethanol consumption, were not
significant.
Allograft biopsies before relapse (12 patients) were not suspicious for alcohol injury. Seven
of 13 patients had liver biopsies after relapse (1–10 biopsies, 2 weeks–4 years), of which only
four had histology (mildly) suspicious for alcohol injury (Table 6). No patient had clear-cut
alcoholic hepatitis. Only one patient had evidence of progressive fibrosis due to alcohol injury
—moderate centrilobular pericellular fibrosis, 4.5 years after relapse. However, interpretation
of the cause of fibrosis was complicated by concurrent hepatitis C infection and rejection-
related central venulitis during this interval.
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Although progressive alcohol injury was generally not seen in biopsies from relapse patients,
they had other progressive liver disease; all five patients who were anti-hepatitis C–positive
before transplant developed recurrent viral hepatitis, with four showing progressive fibrosis
(maximum modified Chronic Hepatitis Fibrosis scores (10): 3/6 in two and 5/6 in the other
two), and the 5th showing de novo hepatitis B on latest biopsy (2543 days after transplant).
Four of the 13 confirmed relapse patients required hospital admission for noninfectious
complications related to drinking, including acute alcohol toxicity, acute rejection after
noncompliance, alcohol-related polyneuropathy, and recurrent acute pancreatitis. Poor
compliance with immunosuppressive therapy was noted for three severely relapsing patients,
two of whom developed chronic rejection in addition to recurrent hepatitis C with fibrosis.
Four confirmed relapse patients died (321–2273 days after transplant): three from infection
and one from a ruptured intracranial aneurysm. Follow-up of the surviving nine confirmed
relapse patients ranged from 2265 to 2931 days. Of the three patients suspicious for relapse
based on histology alone, one died (sepsis, 2019 days), and two survived (at 2711 and 2737
days follow-up).
Other Causes of Allograft Dysfunction
One hundred nineteen allografts (97%) had primary function. Twenty-six (22%) patients
developed major biliary or vascular complications. These included 3 (2%) with biliary
anastomotic leaks and 16 (13%) with bile duct strictures, of which 4 were associated with
hepatic artery stenosis or thrombosis. Eleven patients (9%) developed allograft artery stenosis
or thrombosis, and one developed portal vein thrombosis related to a chronic inflammatory
pancreatic mass. We sought pretransplant factors that predicted these major biliary/vascular
complications: univariate analyses identified high estimated lifetime (P=0.0001) and daily
(P=0.0008) ethanol consumption. In addition, donor age (P=0.03; younger donor = fewer
complications) and lifetime ethanol consumption were only marginally significant in a
bivariate model (P=0.11 without an influential outlier). The duration of sobriety pretransplant,
hepatitis C serology, and various native liver histological parameters were not predictive.
Biopsy-proven acute rejection affected 71 (60%) functioning allografts and was of moderate
or severe intensity in 19 (16%). Forty-five (38%) patients had only a single acute rejection
episode (range 1–5 episodes). The first rejection episode occurred later in patients with longer
pretransplant sobriety (P<0.02). Chronic rejection affected three patients (2%) (321–1135
days), all of whom had poor compliance with the recommended immunosuppression. However,
there was no significant difference in the rate of late-onset (>6 months) acute or chronic
rejection between alcoholic patients that relapsed and those that did not or between the alcoholic
cohort and the nonalcoholic controls (data not shown).
Sixteen (13%) patients showed chronic bile duct injury on biopsy. Proportional hazards
regression using time-dependent covariates was used to evaluate the maximum and minimum
liver biochemistry values during serial 6-month intervals after transplantation. Patients with
chronic bile duct injury on liver biopsy had higher maximum and minimum GGTP (P<0.001
and 0.0001, respectively), SGOT (P<0.04 and 0.01, respectively), and higher minimum SGPT
(P<0.05), compared with other transplanted alcoholics without chronic bile duct injury. The
predictors of chronic bile duct injury were hepatitis C infection (P<0.04), and pericellular
fibrosis on biopsy (P<0.01). Four (3%) patients had Cytomegalovirus graft infection (38–169
days).
Twenty patients showed hepatitis B or hepatitis C infection after transplant (Table 7). Hepatitis
C recurred in 14 of 19 patients seropositive before transplant and was diagnosed on biopsy
with positive serology—with confirmatory RT-PCR or branched chain DNA assays in 9 of 14
cases. Nine of 14 patients with recurrent hepatitis C developed fibrosis stage 3 (of 6) or worse
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on biopsy, including two stage 5 and one cirrhosis. Two additional patients developed hepatitis
C antibodies after transplantation and showed hepatitis without fibrosis on biopsy (679, 1859
days; donor serology was negative). Fibrosis in hepatitis C infection progressed faster in
relapsers compared with nonrelapsers, but numbers were small and the difference was not
significant.
Patients who underwent transplantation for alcoholic liver disease alone had fewer graft
biopsies than nonalcoholic controls transplanted for hepatitis C disease (median 4 vs. 6 per
patient, P=0.009). Moreover, hepatitis C–seropositive alcoholics had more graft biopsies than
hepatitis C seronegative alcoholics (median eight vs. four per patient, P=0.0107). Hepatitis B
recurred in the patient with hepatitis B surface antigen pretransplant and affected five patients
who were seronegative pretransplant (donor serology was negative). Since liver allograft
biopsies in our population are carried out largely because of liver allograft dysfunction, the
above results are at least one way of showing that recurrent hepatitis C disease has a greater
impact on allograft dysfunction than recurrent alcohol abuse.
In a univariate model, viral hepatitis in the allograft was a marginally significant predictor of
allograft failure, although numbers were small (hepatitis C alone: P=0.07; hepatitis C or
hepatitis B: P=0.073). Multiple regression analyses for independent predictors of graft failure
identified development of “mechanical” biliary or vascular complications (P=0.01); chronic
bile duct injury on biopsy (P=0.002), and pericellular fibrosis on biopsy (P<0.05). When
analyses of outcomes were repeated comparing those with lifetime ethanol consumption ≥600
kg vs. <600 kg (men) or ≥150 kg vs. <150 kg (women) with those with daily ethanol
consumption ≥60 g vs. <60 g (men) or ≥20 g vs. <20 g (women) there were no significant
differences.
DISCUSSION
Patients with cirrhosis and a history of excessive alcohol use are labeled as having alcoholic
liver disease, a term that may inappropriately combine a social/psychiatric designation with a
statement of etiology for liver disease. Two main reasons explain the difficulties in estimating
the contribution of alcohol to cirrhosis. First, micronodular cirrhosis may evolve toward a
macronodular pattern (12). In such cases, which are often without earlier biopsy, the final
histology might be indeterminate for cause. Second, at least 31% of the patients in this and
other studies had coexistent conditions that alone could have been the indication for liver
transplantation (7,13–18). Indeed, native livers from hepatitis C–infected patients here and in
other studies often showed morphology of chronic hepatitis rather than alcohol injury (Table
1), suggesting that alcohol had exacerbated viral damage rather than the other way around
(19,20). In alcoholics, the presence and severity of clinical liver disease correlate with hepatitis
C seropositivity (17,21); alcohol may increase hepatitis C replication and liver injury (22) and
accelerate fibrosis (23). Hence, such cases might be better regarded as a subgroup of the
coexistent diagnosis (hepatitis C) rather than alcohol liver disease, especially when considering
the impact of pretransplant diagnosis on graft outcome.
Alcoholic liver disease is cured by transplantation, but a legacy of social and systemic injury
remains. The most serious medical predisposition is to malignancy (24), which was common
—particularly aerodigestive carcinomas—and caused death in this and other studies (25–28).
This is likely attributable to heavy smoking in addition to alcohol problems; however, we were
unable to obtain smoking histories in both the study subjects and controls. Regardless, thorough
otorhinolaryngology screening should be carried out before listing alcoholic patients for
transplantation (27).
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In contrast to some reports (27,29) and its frequent use as a screening criterion (30,31),
pretransplant sobriety shorter than 6 months did not predict relapse in this or in previous studies
at our center (34) and elsewhere (32–36). In our cohort, daily ethanol consumption better
predicted relapse, perhaps because it better indicates the severity of addiction (37). No explant
histological feature in this or another (38) study predicted relapse, unlike with Conjeevaram
et a1., who correlated Mallory bodies with relapse (16). The finding of many Mallory bodies
in 16% of explants in the Conjeevaram study (16), compared with small foci in 33% explants
here, suggest different pretransplant drinking behaviors.
The contribution of relapse to morbidity after transplantation has proved difficult to define
(14,39). Prospective studies show relapse in 34% to 95% of selected patients (14,32,40), and
we have started a prospective study of alcohol use after transplant for alcoholic liver disease.
Here we probably underidentified relapse; we relied largely on liver injury test abnormalities,
patient reports of alcohol use, blood alcohol tests, and clinical suspicion through drinking
patterns that could not be concealed. For less severe consumption, covert drinking may be
difficult to detect.
Hepatic manifestations of relapse might include alcoholic liver disease, alcohol exacerbation
of coexistent conditions such as hepatitis C, or late-onset acute or chronic rejection because of
noncompliance (41). Here, recurrent alcohol liver disease was limited to steatosis (42) and was
not responsible for progressive fibrosis. These results compare favorably with others: allograft
alcoholic hepatitis and cirrhosis after relapse are well described (5,16,43,44), but are
uncommon and rarely cited as a significant cause of graft failure (6,27,30). Steatosis affected
fewer than 10% of patients after 7 years follow-up, compared with much higher recurrence
rates for autoimmune liver diseases or viral hepatitis (15–25% and >50%, respectively), with
a proportion of the latter developing cirrhosis by that time. The possibility that alcohol relapse
might accelerate hepatitis C–related fibrosis in allografts needs further study. Such studies
should evaluate both alcoholic and nonalcoholic hepatitis C–infected patients (7,42,45–47),
because nonalcoholic recipients report alcohol use after transplant as frequently as alcoholic
ones (48). Late onset acute and chronic rejection attributable to poor compliance was a
manifestation of heavy relapse, as reported (30), but was uncommon in this and other studies
of those transplanted for alcoholic liver disease (5,30,49). Indeed, late-onset acute and chronic
rejection were not significantly more common in relapsers than in nonrelapsers or in alcoholics
versus nonalcoholic controls.
The infrequency of alcoholic liver disease after transplantation could be due to effective
recipient screening, alcohol abuse short of the threshold needed for liver disease, short follow-
up (50), factors that render the new liver alcohol-resistant, or any combination of these.
Determinants of the alcohol threshold for liver disease probably include liver-intrinsic
properties, because only about 20% of alcohol abusers develop clinical liver disease (21,51,
52). There is a genetic predisposition to alcohol-related cirrhosis (53), perhaps involving
polymorphic genes that also influence drinking behavior (54,55), such as mitochondrial
aldehyde dehydrogenase (56,57). Study of relapsing alcoholic patients who do and do not
develop alcoholic liver disease in the allograft might facilitate identification/understanding of
allelic regulators of progressive alcohol-related liver injury.
Although recurrent alcohol liver disease was not a problem, heavy relapse clearly imposed
health problems, reflected by admissions for noninfective complications and deaths from
systemic infections (15,27,30,39,49,58). Even so, our results are similar to other studies in
which only 10% to 13% of patients had alcohol relapse that caused physical morbidity or
mortality (59,60). More importantly, this study reaffirms the good graft and patient survival
of those transplanted for alcoholic liver disease, comparable with results in other liver diseases
(7), and support our continuing relatively “liberal” selection policy.
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We were able to identify clinical and histological factors predictive of graft failure. Major
biliary and vascular complications are not surprising, while biopsy evidence of pericellular
fibrosis or focal chronic bile duct injury is more subtle, but nonspecific, evidence of significant
graft injury. Focal chronic bile duct injury has also been associated with hepatitis C infection
before (61,62), as we found here.
Past studies have found a lower acute rejection incidence in transplanted alcoholics, compared
with other disease indications (63,64), but more detailed correlations within the alcohol group
have not been reported. The present suggestion that long pretransplant sobriety is associated
with freedom from early acute rejection is nevertheless difficult to rationalize.
In conclusion, alcoholism is a brain-centered addictive disorder in which people submit
themselves to an alcohol-rich environment that can damage many tissues. Those presenting
for liver transplantation might seem to be preselected for proclivity to alcohol-induced liver
disease, but this study shows that up to 30% have coexistent diseases that alone could have
necessitated liver transplantation. We found recurrent alcohol liver disease to be a relatively
benign disorder by comparison with recurrent viral and autoimmune liver disease and not an
important cause of graft failure. Nevertheless, heavy relapse in a minority of patients can
shorten survival, primarily through infectious complications, and may accelerate progression
of recurrent viral hepatitis.
Thus, in those without coexistent conditions, alcoholic liver disease is an excellent indication
for liver transplantation. A new liver introduces a new genetic variable, which could potentially
delay recurrent liver disease, even in severe relapse. Our data are insufficient to determine
whether this is true, but consistent with the hypothesis. However, chronic alcohol-induced and
other addictive behavior-induced injury (e.g. smoking) of other target continues to evolve, of
which carcinogenesis may be accelerated by immunosuppression (65). Hence, patients should
be heavily screened for other target organ damage, which is a greater cause of morbidity and
mortality than recurrent alcohol liver disease.
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TABLE 1
Histologic determinations of prevalent injuries in 123 explanted native livers, relative to assessment of alcohol
injury
Histopathologic evidence for
alcohol-related liver injury
Number of patients Histopathology suspicious for
HCV/HCV seropositive cases
Histopathology of coexistent conditions (n)
None/minimal 67 (54%) 9/11 (82%) hemochromatosis (3)
α1-antitrypsin deficiency (2)
epithelioid granulomas, unknown cause (2)
HBV + acute acetaminophen toxicity (1)
? viral hepatitis, but seronegative (6)
Mild 25 (20%) 0/3 hemochromatosis (4a)
α1-antitrypsin deficiency (2)
sarcoid (1)
Moderate/strong 31 (25%) 1/6 (17 %) hemochromatosis (2)
α1-antitrypsin deficiency (1)
a
One patient had evidence of both hemochromatosis and α1-antitrypsin deficiency. HCV, hepatitis C.
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Table 2
Correlation of duration of sobriety before transplantation with steatosis and Mallory's bodies in the explanted
native liver
Sobriety (months) Mallory's bodiesa Steatosisb
1–6 18/32 (56%) 21/32 (66%)
7–24 9/41 (22%) 14/41 (34%)
>24 11/46 (24%) 19/46 (41%)
Sobriety duration was known in 119 patients. Mallory's bodies: central nodular location required to eliminate examples due to cholatestasis
(aP=0.0044; bP=0.0201). The analysis was done using two different logistic regression models. Mallory bodies and steatosis were the two dichotomous
outcomes and pretransplant sobriety was the independent variable. Thus, the one univariate model indicated that pretransplant sobriety does affect
Mallory bodies, and the other univariate model indicated that pretransplant sobriety affects steatosis.
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Table 3
Causes of death or graft failure in the first 6 months after transplantation (first graft only)
Number of patients Time range (days)
Cause of death
Cardiovascular 2 1–2
Infection 9 21–159
Graft failure without death
Primary nonfunction 4 0
Hepatic artery thrombosis 2 6–15
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Table 4
Causes of death or graft failure after 6 months (first graft only) (n=35)
Cause of death Graft disease Patient number (%) Time range (days) Comments
Cardiovascular 3 (9) 1805–2351
Suicide 1 (3) 370
PTLD 2 (6) 783, 1841
Recurrent HCC 3 (9) 265–1316
New malignancy (invasive
carcinomas)
7 (20) 577–2169 upper aerodigestive (5)
lung (1)
uncertain primary (1)
Infection HCV +cr+strictures (1)
HCV (1)
chronic bile duct injury (1)
5 (14) 236–2100 lung (3)
abdomen (1)
infected thrombus (1)
Hepatic encephalopathy HCV+cr 1 (3) 1602 post-TIPSS encephalopathy
Unknown No evidence 7 (20) 198–2636 transitional cell carcinoma (2)
Graft failure without death
Hepatic artery thrombosis 3 (9) 1126–1339
Biliary strictures 2 (6) 291, 1731
HCV 1 (3) 1604
HCC, hepatocellular carcinoma; HCV, hepatitis C infection; cr, chronic rejection; strictures, bile duct strictures; PTLD, posttransplant
lymphoproliferative disorder; TIPSS, transjugular intrahepatic portosystemic shunt.
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Table 5
New extrahepatic malignancies after transplantation
Primary Histology Number of tumors in
alcohol cohort
Histology Number of tumors in
control cohort
Upper aerodigestive Squamous 8 Squamous 2
Genitourinary Transitional cell (4),
Prostate adenocarcinoma
(2)
6 Prostate adenocarcinoma 3
Lung Squamous (2), Small cell
(1)
3 Adenocarcinoma 2
Colorectal Adenocarcinoma 2 Adenocarcinoma 3
Hematological (not PTLD) Follicle centre cell
lymphoma
1 Acute myeloid leukaemia 1
Unknown Clear cell carcinoma 1 Adenocarcinoma 1
Other 0 Breast adenocarcinoma (1),
Thyroid papillary (1), Duodenal
Kaposi sarcoma
3
Skin Squamous (10), Basal cell
(1), Melanoma (1)
12 Squamous (2), Basal cell (5),
Melanoma (1), Kaposi (1)
9
Total 33 (27/123pts) 24 (24/390pts)
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Table 6
Histopathological findings in allograft biopsies obtained after alcohol relapse
Patient Days after transplant Features suspicious for alcohol injury Coexistent graft disease Alcohol injury on later biopsies
1 210 None HCV; cr No (autopsy liver: 321 days)
2 465 Steatosis, rare Mallory HCV No (771, 946, 2300 days)
3 443 Marginal steatohepatitis HCV; cr Moderate pericellular fibrosis (1812
days)
4 1115 Mild steatofibrosis None No (1521, 1581 days)
5 1364 Steatosis HCV Marginal steatohepatitis (2543
days)
6 2288 None None N/A
7 2805 None HCV N/A
Allograft biopsies suspicious for alcohol injury, from patients without other evidence for relapse
1 1098 Steatosis None No (1393, 1544 days)
2 1193 Mild steatofibrosis None N/A
3 1281 Steatosis, rare Mallory None Marginal steatohepatitis (1968
days)
Steatosis, centrilobular steatosis; Mallory, centrilobular Mallory's bodies; Marginal steatohepatitis, steatosis with minimal acute inflammation,
borderline for low grade steatohepatitis; Steatofibrosis, steatosis with perivenular and pericellular fibrosis, suggestive of inactive steatohepatitis; cr,
chronic rejection.
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TABLE 7
Viral hepatitis after transplant (20 patients)
Infection Number of patients Diagnosis (days after transplant) Maximum modified HAI fibrosis score on biopsy
HBV, recurrent 1 1163 3
HBV, new onset 5 169–2543 0–6
HCV, recurrent 14 45–1364 0–6
HCV, new onset 2 679, 1859 0
(note: 2 patients developed both HBV and HCV graft infection) HAI, hepatitis activity index; HBV, hepatitis B; HCV, hepatitis C.
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